The J. M. Smucker Company (SJM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Jun, 2026Executive summary
Annual Meeting scheduled for August 12, 2026, to be held virtually, with shareholders of record as of June 15, 2026, eligible to vote.
Fiscal 2026 net sales reached $9.1 billion (up 4%), adjusted EPS was $9.15 (down 10%), and free cash flow was $1.2 billion (up $339.6 million).
$464.7 million was returned to shareholders via dividends in fiscal 2026.
Strategic focus for fiscal 2027 includes driving organic growth, improving margins and profitability, and fostering an enterprise mindset.
Voting matters and shareholder proposals
Shareholders will vote on: election of 11 directors, ratification of Ernst & Young LLP as auditor for FY2027, and advisory approval of executive compensation.
Board recommends voting FOR all proposals.
Proxy access allows groups of up to 20 shareholders owning at least 3% for three years to nominate directors.
Board of directors and corporate governance
Board consists of 11 directors, 10 of whom are independent; 4 are women and 3 are racially/ethnically diverse.
Five new directors have joined since 2022, with ongoing refreshment and rotation of committee chairs.
Lead Independent Director coordinates independent director activities; regular executive sessions are held.
Board committees: Audit, Compensation, and Nominating, all comprised of independent directors.
Board succession planning and director education are emphasized.
Latest events from The J. M. Smucker Company
- Key votes include board elections, auditor ratification, and executive pay approval.SJM
Proxy filing26 Jun 2026 - Q4 saw strong sales and profit growth; FY27 expects lower sales but higher adjusted EPS.SJM
Q4 2026 [Q&A]9 Jun 2026 - Q4 saw strong profit growth and cash flow; FY27 expects lower sales but higher adjusted EPS.SJM
Q4 2026 Prepared Remarks9 Jun 2026 - Net sales rose 7% and adjusted EPS fell 9%, with $961.7M in impairments and FY26 guidance reaffirmed.SJM
Q3 2026 [Q&A]10 Apr 2026 - Net sales rose 7% but adjusted EPS fell 9% amid $961.7M impairment and mixed segment results.SJM
Q3 2026 Prepared Remarks26 Feb 2026 - Organic growth, innovation, and margin expansion drive record sales and shareholder value.SJM
Consumer Analyst Group of New York Conference (CAGNY) 202618 Feb 2026 - Growth, innovation, and disciplined capital deployment support $1B+ free cash flow and value.SJM
Consumer Analyst Group of New York Conference 20253 Feb 2026 - Strong results, strategic focus, and all proposals passed amid ongoing debt reduction and leadership changes.SJM
AGM 20253 Feb 2026 - Key brands fuel growth amid inflation, with innovation and expansion supporting future gains.SJM
BofA Securities Consumer and Retail Conference 20253 Feb 2026